Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
To continue, to switch or just following up? Source: Annual Congress 2012 - Award for Achievement in the field of NSCLC Ceremony (supported by AstraZeneca) followed by Grand Round "How to diagnose and manage NSCLC with the new drugs" - an interactive session Year: 2012
TB vaccination: why, when, how and what? Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults Year: 2014
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
How to stop the bleed? Source: Virtual Congress 2021 – CCC Respiratory critical care Year: 2021
Motivating patients to stop doing something: smoking cessation Source: Annual Congress 2013 –PG8 How to encourage compliance with therapy Year: 2013
Positional therapy: who, when and how? Source: Sleep and Breathing Conference 2021 Year: 2021
Patient selection? One fits all (monotherapy versus combined therapy)? Source: Sleep and Breathing Conference 2021 Year: 2021
Group-delivered speech and language therapy for chronic refractory cough: what do patients want? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017
COVID-19 mRNA vaccines: a step forward from traditional vaccines? Source: Virtual Congress 2021 – Scientific year in review Year: 2021
When to start and when to stop antifibrotic therapies Source: Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017 Year: 2017
How to stop LC-fILD progression: an overview of modern therapeutic strategies Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021
Can we expect progress from targeted therapy of SCLC? Source: Eur Respir Monogr 2015; 68: 234-246 Year: 2015
What could we learn from ongoing therapeutic trials? Source: ERS Research Seminar Year: 2015
Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011